Dr. George Golumbeski

1957
US-American
Far Hills, NJ, USA
2018



Professional development

Since 2018	Freelance business consultant in the life sciences and healthcare industries
2018 - 2019	President, Grail Inc., Menlo Park, CA, USA
2017 – 2018	Executive Vice President & Executive Advisor for Innovation, Celgene Corporation, Summit, NJ, USA
2009 – 2017	Executive Vice President, Business Development, Celgene Corporation, Summit, NJ, USA
2008 – 2009	Chief Executive Officer, Nabriva Therapeutics AG, Vienna, Austria
2002 – 2008	Vice President, Business Development, Licensing & Strategy, Novartis Oncology, Florham Park, NJ, USA
2001 – 2002	Vice President, R&D Business Development, Elan Biopharmaceuticals, San Diego, CA, USA
2000 – 2001	Senior Director, Licensing, EMD Pharmaceuticals, Durham, NC, USA
1997 – 2000	Vice President / Director, Corporate Development, Schwarz Pharma, Mequon, WI, USA
1996 – 1997	Director, Business Development, Pierce Chemical Company, Rockford, IL, USA
1991 – 1995	Technology Acquisition Manager / Group Leader, Research & Development / Group Leader, Diagnostics Research & Development, Promega Corporation, Madison, WI, USA

Education

1986 – 1991	Postdoctoral Research, Molecular biology, University of Colorado Boulder, Boulder, CO, USA
1979 – 1985	Ph.D., Genetics, University of Wisconsin-Madison, Madison, WI, USA
1975 – 1989	B.A., Biology, University of Virginia, Charlottesville, VA, USA

Memberships in statutory supervisory boards and/or in comparable domestic or foreign supervisory bodies of commercial enterprises

Ananke Therapeutics, Inc., Boston, MA, USA* Carrick Therapeutics Ltd., Dublin, Ireland* Sage Therapeutics, Cambridge, MA, USA Shattuck Labs, Inc., Austin, TX, USA Actio Biosciences, San Diego, CA, USA* Chroma Medicine, Cambridge, MA, USA* Chairman of the Board of Directors Chairman of the Board of Directors Member of the Board of Directors Chairman of the Board of Directors Chairman of the Board of Directors Member of the Board of Directors

*not publicly listed company

As of April 2023